Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 4/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243804 | 1.00 | AHR (0.49) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL30351303 | 0.88 | AHR (0.49) | AHRLPLLIPGPDK2CMA1 | |
| SCHEMBL392563 | 0.88 | AHR (0.49) | AHRLPLLIPGPDK2CMA1 | |
| SCHEMBL422134 | 0.87 | PDE3B (0.44) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL30320628 | 0.84 | MAPT (0.46) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL28383719 | 0.84 | MAPT (0.46) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL12049915 | 0.81 | AHR (0.42) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL9953566 | 0.81 | AHR (0.42) | AHRGRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL1857437 | 0.81 | AHR (0.64) | AHRLPLLIPGPDK2CMA1 | |
| SCHEMBL429226 | 0.79 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112086564-A | Passivating agent and passivation method thereof and method for preparing semiconductor film | 杭州纤纳光电科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-111435705-A | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2020-07-21 | — | — | CN | claimed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304600-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | IYENGAR RAJESH R | 2006-12-21 | — | — | US | disclosed |
| US-7119205-B2 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBOTT LABORATORIES (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304600-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | AHR 3031/4885GRIA1 1524/4885CACNG8 3264/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | AHR 2515/4885GRIA1 144/4885CACNG8 885/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | AHR 4553/4885GRIA1 484/4885CACNG8 229/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | AHR 1501/4885GRIA1 206/4885CACNG8 1066/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | AHR 271/4885GRIA1 698/4885CACNG8 2075/4885 |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | GPR119, FABP4, ADIPOR1 | AHR 467/4885GRIA1 2280/4885CACNG8 2523/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | AHR 3249/4885GRIA1 1358/4885CACNG8 3861/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | AHR 363/4885GRIA1 76/4885CACNG8 144/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | AHR 1138/4885GRIA1 2732/4885CACNG8 3161/4885 |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | AHR 1479/4885GRIA1 1026/4885CACNG8 4665/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | AHR 3249/4885GRIA1 1358/4885CACNG8 3861/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | AHR 225/4885GRIA1 197/4885CACNG8 243/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | AHR 958/4885GRIA1 683/4885CACNG8 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.